

PATENT COOPERATION TREATY

PCT

Rec'd PCT/PTO 09 SEP 2004

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

RECEIVED

01 SEP 2004

WIPO


PCT

Applicant's or agent's file reference MGC020325	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/07388	International filing date (day/month/year) 10 March 2003 (10.03.2003)	Priority date (day/month/year) 25 March 2002 (25.03.2002)
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 31/4439, 31/444; C07D 417/14, 413/14 and US Cl.: 514/210.2; 546/268.1, 256		
Applicant LUO, JIAN		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of ___ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 20 October 2003 (20.10.2003)	Date of completion of this report 23 August 2004 (23.08.2004)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer  Vickie Kim Telephone No. 571-272-1600

Form PCT/IPEA/409 (cover sheet)(July 1998)

BEST AVAILABLE COPY

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US03/07388

I. Basis of the report

1. With regard to the elements of the international application:*

☒ the international application as originally filed.☒ the description:

pages 1-9 as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of _____.

☒ the claims:

pages 10 and 11 as originally filed

pages NONE, as amended (together with any statement) under Article 19

pages NONE, filed with the demand

pages NONE, filed with the letter of _____.

☒ the drawings:

pages 1, as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of _____.

☐ the sequence listing part of the description:

pages NONE, as originally filed

pages NONE, filed with the demand

pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☐ The amendments have resulted in the cancellation of:☐ the description, pages NONE☐ the claims, Nos. NONE☐ the drawings, sheets/fig NONE5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/07388**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>NONE</u>	YES
	Claims <u>1-10</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-10</u>	NO
Industrial Applicability (IA)	Claims <u>1-10</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-10 lack novelty and inventive step under PCT Article 33(2)-(3) as being anticipated by or obvious over WO98/05331, (Chen WO '331).

Chen (WO'331) teaches a pharmaceutical composition comprising PPARalpha(e.g. gemifrozil), PPARgamma agonist(e.g. troglitazone) and metformin, see abstract and page 13, line 8. Although metformin is listed as an additive agent, the combination comprising metformin and gemfrozil is embraced by the patented invention. As to the claims 4-10, the minor variations such as routes of administration, dosage regimen including specific ratios between each active ingredient to determine most effective therapy would have been considered to be conventional and commonly practiced. The techniques are within the skilled level of the artisan having ordinary skill in the art, and this obvious, absent evidence to the contrary. Thus, the claimed subject matter lacks novelty nor inventive steps.

Claims 1-10 meet the criteria set out in PCT Article 33(4), and thus the instant invention has industrial applicability because the subject matter claimed can be made or used in industry.

Applicant's argument filed 19 July 2004 is carefully considered but not persuasive because the claimed invention is taught and embraced by the scope of the patented invention. Although the claims uses different terminology, the claimed invention having same structure(e.g. a composition containing meformin and gemifrozil) is taught and the claims are met. It is also reminded that the claims are drafted broadly wherein the patented invention of the prior art of the record met the claimed invention. For the reasons set for the above, the claims are properly included in this rejection.